StreetInsider.com News Articles

Form 4 Taysha Gene Therapies, For: Jul 10 Filed by: Nagendran Sukumar

Fri, 10 Jul 2026 18:55:00 -0400

si-local-file:///var/storage/secattach/20260710/26758243.html

Form 4 Taysha Gene Therapies, For: Jul 10 Filed by: Nagendran Sukumar

Fri, 10 Jul 2026 18:55:00 -0400

si-local-file:///var/storage/secattach/20260710/26758243.html

Form 144 Taysha Gene Therapies, Filed by: Nagendran Sukumar

Fri, 10 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260710/26757566.html

Form 144 Taysha Gene Therapies, Filed by: Nagendran Sukumar

Fri, 10 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260710/26757566.html

Taysha Gene Therapies (TSHA) Reiterated at Market Outperform by Citizens

Thu, 02 Jul 2026 04:19:24 -0400

Citizens analyst Silvan Tuerkcan reiterated a Market Outperform rating and $11.00 price target on Taysha Gene Therapies (NASDAQ: TSHA).

The analyst commented, "Overall, we come away positive from the meeting for TSHA-102 and recommend the stock ahead of pivotal data and regulatory feedback in 1H27. At a high level, attendees were convinced by the early results, with an emphasis on improved communication and grasping, which have a very high impact on QoL. "How can we compare pivotal efficacy across programs?" remained unanswered. To our surprise, doctors at centers of excellence and patients did not mind Neurogene's (NGNE, NC) more-involved ICV delivery

Taysha Gene Therapies (TSHA) Reiterated at Market Outperform by Citizens

Thu, 02 Jul 2026 04:19:24 -0400

Citizens analyst Silvan Tuerkcan reiterated a Market Outperform rating and $11.00 price target on Taysha Gene Therapies (NASDAQ: TSHA).

Taysha Gene Therapies (TSHA) PT Raised to $15 at Baird

Mon, 29 Jun 2026 13:53:39 -0400

Baird analyst Jack Allen raised the price target on Taysha Gene Therapies (NASDAQ: TSHA) to $15.00 (from $12.00) while maintaining a Outperform rating.

Form 8-K Taysha Gene Therapies, For: Jun 24

Thu, 25 Jun 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260625/26692712.html

Form 8-K Taysha Gene Therapies, For: Jun 24

Thu, 25 Jun 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260625/26692712.html

Form 424B5 Taysha Gene Therapies,

Thu, 25 Jun 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260625/26692687.html

Form 424B5 Taysha Gene Therapies,

Thu, 25 Jun 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260625/26692687.html

Taysha Gene Therapies to present TSHA-102 data at 2026 Rett meeting

Thu, 25 Jun 2026 16:01:40 -0400

Taysha Gene Therapies (Nasdaq: TSHA) announced it will present multiple data sets from its TSHA-102 clinical program at the 2026 International Rett Syndrome Foundation Scientific Meeting in Prior Lake, MN, running June 29 through July 1, 2026.

The presentations include an oral session and three poster presentations covering clinical, natural history, and preclinical data related to TSHA-102, an investigational intrathecally delivered AAV9 gene therapy in development for Rett syndrome.

Clinical data from the REVEAL Part A Phase 1/2 trial will be presented by Elsa Rossignol, M.D., a principal investigator of the trial and professor at the Université de Montréal. According to the

Taysha Gene Therapies to present TSHA-102 data at 2026 Rett meeting

Thu, 25 Jun 2026 16:01:40 -0400

Clinical data from the REVEAL Part A Phase 1/2 trial will be presented by Elsa Rossignol, M.D., a principal investigator of the trial and professor at the Université de Montréal. According to the

Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting

Thu, 25 Jun 2026 16:01:00 -0400

Recently disclosed longer-term REVEAL Part A data demonstrated broad, multi-domain functional impact that deepened over time through ≥12 months post-TSHA-102 regardless of age or disease severity

Rett syndrome natural history data analysis shows a clear developmental plateau after 6 years of age, supporting a stable, well-defined population to evaluate TSHA-102 in the REVEAL pivotal trial

New data support the developmental milestone assessment (DMA) as a psychometrically valid, FDA-supported primary endpoint for single-arm interventional studies

Preclinical data demonstrated superior MeCP2 expression of self-complementary AAV9 compared to single-stranded, supporting effective CNS delivery of TSHA-102 by

Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting

Thu, 25 Jun 2026 16:01:00 -0400

Recently disclosed longer-term REVEAL Part A data demonstrated broad, multi-domain functional impact that deepened over time through ≥12 months post-TSHA-102 regardless of age or disease severity

Rett syndrome natural history data analysis shows a clear developmental plateau after 6 years of age, supporting a stable, well-defined population to evaluate TSHA-102 in the REVEAL pivotal trial

New data support the developmental milestone assessment (DMA) as a psychometrically valid, FDA-supported primary endpoint for single-arm interventional studies

Preclinical data demonstrated superior MeCP2 expression of self-complementary AAV9 compared to single-stranded, supporting effective CNS delivery of TSHA-102 by

Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting

Thu, 25 Jun 2026 16:01:00 -0400

Recently disclosed longer-term REVEAL Part A data demonstrated broad, multi-domain functional impact that deepened over time through ≥12 months post-TSHA-102 regardless of age or disease severity

Rett syndrome natural history data analysis shows a clear developmental plateau after 6 years of age, supporting a stable, well-defined population to evaluate TSHA-102 in the REVEAL pivotal trial

New data support the developmental milestone assessment (DMA) as a psychometrically valid, FDA-supported primary endpoint for single-arm interventional studies

Preclinical data demonstrated superior MeCP2 expression of self-complementary AAV9 compared to single-stranded, supporting effective CNS delivery of TSHA-102 by

Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting

Thu, 25 Jun 2026 16:01:00 -0400

Recently disclosed longer-term REVEAL Part A data demonstrated broad, multi-domain functional impact that deepened over time through ≥12 months post-TSHA-102 regardless of age or disease severity

Rett syndrome natural history data analysis shows a clear developmental plateau after 6 years of age, supporting a stable, well-defined population to evaluate TSHA-102 in the REVEAL pivotal trial

New data support the developmental milestone assessment (DMA) as a psychometrically valid, FDA-supported primary endpoint for single-arm interventional studies

Preclinical data demonstrated superior MeCP2 expression of self-complementary AAV9 compared to single-stranded, supporting effective CNS delivery of TSHA-102 by

Taysha Gene Therapies prices $200M public stock offering

Wed, 24 Jun 2026 22:33:46 -0400

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced the pricing of an underwritten public offering of 32,500,001 shares of common stock at $6.00 per share, according to a company press release.

The clinical-stage biotechnology company is also offering pre-funded warrants to purchase 833,333 shares of common stock at $5.999 per warrant to certain investors in lieu of common stock. All securities are being offered by Taysha.

Gross proceeds from the offering are expected to be approximately $200.0 million, before underwriting discounts, commissions, and other offering expenses, excluding any exercise of the underwriters' option to purchase additional shares.

Taysha has granted underwriters a 30-day option

Taysha Gene Therapies prices $200M public stock offering

Wed, 24 Jun 2026 22:33:46 -0400

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced the pricing of an underwritten public offering of 32,500,001 shares of common stock at $6.00 per share, according to a company press release.

The clinical-stage biotechnology company is also offering pre-funded warrants to purchase 833,333 shares of common stock at $5.999 per warrant to certain investors in lieu of common stock. All securities are being offered by Taysha.

Gross proceeds from the offering are expected to be approximately $200.0 million, before underwriting discounts, commissions, and other offering expenses, excluding any exercise of the underwriters' option to purchase additional shares.

Taysha has granted underwriters a 30-day option

Taysha Gene Therapies prices $200M public stock offering

Wed, 24 Jun 2026 22:33:46 -0400

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced the pricing of an underwritten public offering of 32,500,001 shares of common stock at $6.00 per share, according to a company press release.

The clinical-stage biotechnology company is also offering pre-funded warrants to purchase 833,333 shares of common stock at $5.999 per warrant to certain investors in lieu of common stock. All securities are being offered by Taysha.

Gross proceeds from the offering are expected to be approximately $200.0 million, before underwriting discounts, commissions, and other offering expenses, excluding any exercise of the underwriters' option to purchase additional shares.

Taysha has granted underwriters a 30-day option

Taysha Gene Therapies prices $200M public stock offering

Wed, 24 Jun 2026 22:33:46 -0400

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced the pricing of an underwritten public offering of 32,500,001 shares of common stock at $6.00 per share, according to a company press release.

The clinical-stage biotechnology company is also offering pre-funded warrants to purchase 833,333 shares of common stock at $5.999 per warrant to certain investors in lieu of common stock. All securities are being offered by Taysha.

Gross proceeds from the offering are expected to be approximately $200.0 million, before underwriting discounts, commissions, and other offering expenses, excluding any exercise of the underwriters' option to purchase additional shares.

Taysha has granted underwriters a 30-day option

Taysha Gene Therapies prices $200M public stock offering

Wed, 24 Jun 2026 22:33:46 -0400

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced the pricing of an underwritten public offering of 32,500,001 shares of common stock at $6.00 per share, according to a company press release.

The clinical-stage biotechnology company is also offering pre-funded warrants to purchase 833,333 shares of common stock at $5.999 per warrant to certain investors in lieu of common stock. All securities are being offered by Taysha.

Gross proceeds from the offering are expected to be approximately $200.0 million, before underwriting discounts, commissions, and other offering expenses, excluding any exercise of the underwriters' option to purchase additional shares.

Taysha has granted underwriters a 30-day option

Taysha Gene Therapies prices $200M public stock offering

Wed, 24 Jun 2026 22:33:46 -0400

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced the pricing of an underwritten public offering of 32,500,001 shares of common stock at $6.00 per share, according to a company press release.

The clinical-stage biotechnology company is also offering pre-funded warrants to purchase 833,333 shares of common stock at $5.999 per warrant to certain investors in lieu of common stock. All securities are being offered by Taysha.

Gross proceeds from the offering are expected to be approximately $200.0 million, before underwriting discounts, commissions, and other offering expenses, excluding any exercise of the underwriters' option to purchase additional shares.

Taysha has granted underwriters a 30-day option

Taysha Gene Therapies prices $200M public stock offering

Wed, 24 Jun 2026 22:33:46 -0400

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced the pricing of an underwritten public offering of 32,500,001 shares of common stock at $6.00 per share, according to a company press release.

The clinical-stage biotechnology company is also offering pre-funded warrants to purchase 833,333 shares of common stock at $5.999 per warrant to certain investors in lieu of common stock. All securities are being offered by Taysha.

Gross proceeds from the offering are expected to be approximately $200.0 million, before underwriting discounts, commissions, and other offering expenses, excluding any exercise of the underwriters' option to purchase additional shares.

Taysha has granted underwriters a 30-day option

Taysha Gene Therapies prices $200M public stock offering

Wed, 24 Jun 2026 22:33:46 -0400

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced the pricing of an underwritten public offering of 32,500,001 shares of common stock at $6.00 per share, according to a company press release.

The clinical-stage biotechnology company is also offering pre-funded warrants to purchase 833,333 shares of common stock at $5.999 per warrant to certain investors in lieu of common stock. All securities are being offered by Taysha.

Gross proceeds from the offering are expected to be approximately $200.0 million, before underwriting discounts, commissions, and other offering expenses, excluding any exercise of the underwriters' option to purchase additional shares.

Taysha has granted underwriters a 30-day option